Optical Tomography Cell Morphometry for Early TMB Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting tumor mutation burden (TMB) are invasive, expensive, and lack sensitivity and specificity, particularly in early-stage cancer detection, limiting the effectiveness of immunotherapy targeting.
Innovation Solution
A non-invasive optical tomography system, such as the Cell-CT platform, generates isometric 3D cell images that utilize automated feature extraction and classification algorithms to identify abnormal cells with high accuracy, enabling the detection of TMB through morphometric changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for detecting TMB are used, then detection accuracy is achieved, but the methods are invasive and expensive
Solution Approach 1:
The patent replaces mechanical/invasive biopsy methods with optical imaging technology. The optical tomography system uses light to non-invasively image cells and detect morphometric biomarkers that correlate with TMB, eliminating the need for tissue sampling while maintaining detection accuracy
Solution Approach 2:
The patent changes the detection parameter from direct genomic sequencing to optical morphometric measurements. By measuring nuclear morphology parameters (size, shape, texture) that correlate with TMB, the system provides an indirect but accurate measurement method that is non-invasive and cost-effective
2Measurement precision
If current TMB detection methods are used, then TMB levels can be measured, but sensitivity and specificity in early-stage cancer detection are limited
Solution Approach 1:
The patent transitions from 2D histopathological images to 3D optical tomography images, adding a dimensional aspect that captures more comprehensive nuclear morphology information. This enables more accurate detection of subtle morphometric changes associated with early-stage cancer and high TMB
3Ease of operation
If immunotherapy is administered without accurate TMB prediction, then treatment can be provided, but unnecessary inflammatory and immune-related adverse effects occur
Solution Approach 1:
The patent performs preliminary non-invasive screening to identify patients with high TMB who are likely to respond to immunotherapy before treatment begins. This preliminary assessment using optical morphometric analysis prevents unnecessary immunotherapy administration to patients who would not benefit, avoiding adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a rapid, minimally invasive method for accurately characterizing TMB, allowing for personalized cancer therapy with reduced side effects by identifying morphometric biomarkers in cancer cells.
Implementation Method 1
Morphometric genotyping of cells using optical tomography for detecting tumor mutational burden
Implementation Method 2
The direct link between the chromatin organization in the cell nucleus and cell function
Data Source
AI summary
A method to develop one or more morphometric classifiers to identify a tumor mutation burden (TMB). The method provides a non-invasive method of characterizing TMB that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.